Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.
Sanofi's experimental oral drug venglustat demonstrated significant neurological benefits for patients with Type 3 Gaucher disease in a late-stage trial, but failed to meet its primary endpoint in a separate study for Fabry disease, casting uncertainty on its regulatory path.
Shares of Perspective Therapeutics (CATX) have rallied sharply following encouraging interim results from its lead cancer therapy trial and a strategic business update. While the data fuels optimism, a deep dive into the numbers reveals a stark disconnect between its current market price and analyst targets, highlighting both opportunity and significant risk.
Biotech firm Definium Therapeutics appoints seasoned commercial executive Roger Adsett to its board, signaling a strategic shift towards commercialization as key late-stage trial data approaches.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
Marius Borg Høiby, the eldest son of Crown Princess Mette-Marit, was taken into custody on fresh allegations of assault and weapons offenses just days before his high-profile trial on multiple rape charges is set to begin, deepening the crisis for Norway's monarchy.
Quince Therapeutics' lead candidate, eDSP, has failed to meet primary and secondary endpoints in its pivotal Phase III NEAT trial for the rare neurological disorder Ataxia-Telangiectasia (A-T), triggering a catastrophic drop in the company's share price.
While the industrial sector has surged ahead of the broader market, not all companies are equally positioned for sustainable growth. We analyze one defense contractor with strong tailwinds and two manufacturers where valuation concerns loom large.
The industrial sector has outperformed the broader market, buoyed by regulatory shifts. However, not all companies are equally positioned. We analyze one stock with a durable edge and two facing potential headwinds.
While the industrial sector has surged ahead of the broader market, not all companies are positioned to weather an economic downturn. We examine three industrial stocks where valuation and business model concerns suggest investors should proceed with caution.
While often operating behind the scenes, industrial companies are the engine of the U.S. economy. Bolstered by a favorable interest rate environment, the sector has surged 18.8% in the last six months, significantly outpacing the S&P 500. We analyze two firms with durable competitive edges and one that may be losing momentum.
Aalberts N.V. (AMS:AALB), a mid-cap specialist in industrial technology, has seen a significant price surge on the ENXTAM, prompting analysts to revisit its valuation and growth trajectory amidst market volatility.
A consortium of nine major corporations, including Google and Singapore Airlines, is launching a voluntary trial for centralized sustainable aviation fuel (SAF) procurement. This pilot, led by the newly formed SAFCo, is a critical step ahead of Singapore's pioneering green levy on departing flights set for October, aiming to refine systems for a 1% SAF usage target.
As Illinois Tool Works prepares to report its fourth-quarter results, investors are weighing steady growth forecasts against a history of revenue misses. The report comes amid a mixed performance for the industrial machinery sector.
W.W. Grainger (GWW) reports quarterly earnings Tuesday morning, with investors watching for signs of sustained growth against a backdrop of mixed industrial sector performance and recent stock gains.
As AMETEK prepares to report its quarterly results, investors are watching to see if the electronics manufacturer can maintain its streak of strong performance amid a mixed landscape for industrial equipment firms.
A commanding 66% insider ownership at CB Industrial Product Holding Berhad (KLSE:CBIP) aligns management's fortunes directly with shareholders, raising questions about governance and future direction in Malaysia's industrial sector.
